Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II clinical study of ALS-4

Next Previous
X
Search
Trial Profile

A Phase II clinical study of ALS-4

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 09 Mar 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ALS 4 (Primary)
  • Indications Bacterial skin diseases; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
  • Focus Therapeutic Use
  • Sponsors Aptorum Group

    • Most Recent Events

    • 03 Mar 2023 According to an Aptorum Group media release, the company has completed the Pre-IND discussions with the US Food and Drug Administration. With the positive feedback on the overall development strategy from the US FDA, the company is now proceeding towards the IND submission of ALS-4.
    • 17 Jan 2022 New trial record
    • 10 Jan 2022 According to an Aptorum Group media release, the company is on track to submit an IND application to the US FDA this year seeking to initiate a Phase 2 clinical study to assess the efficacy of ALS-4 in patients.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top